Skip to main content
. 2015 Jan 22;4(3):e994391. doi: 10.4161/2162402X.2014.994391

Figure 3.

Figure 3.

The in vitro antitumor effects of Tras-Permut CrossMab. (A), the anti-proliferation effect of Tras-Permut CrossMab (100 nmol/L) was evaluated by MTS assay. Mean ± SD (n = 3). *p < 0.05. (B), induction of cell death by Tras-Permut CrossMab (10 μg/mL) in the absence of ligands was assessed by staining with SYTOX® Red and FCM. The graphs are representative of at least three experiments, each of which showed similar results. *p < 0.05. (C), ADCC activity against BT-474 cells using human PBMCs as effector cells at E/T ratio of 25:1. The ADCC activity of Tras-Permut CrossMab was measured using a standard LDH assay as described in “ADCC assays.” Data are mean ± SD (n = 3). *p < 0.05.